Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
News Jan 12, 2012
Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE diagnosis. Specifically, the panel includes testing of ANA, dsDNA, Avise MCV, EC4d and BC4d. The Avise SLE diagnostic differentiates itself by using cell-bound complements because of their increased performance over soluble complements which helps to accurately and consistently diagnose SLE.
Avise SLE is most impactful when ordered as a first step in patient treatment to help physicians with diagnosis by providing:
• Efficiency - 5 individual markers, 1 blood draw
• Confidence in Diagnosis - From a panel that rules-in SLE and rules-out other rheumatic diseases
• Increased Accuracy - Using CB-CAPs technology to achieve 78% sensitivity and 87% specificity for other diseases/97% specificity for normal/healthy patients
• Convenience - We provide kits, pay shipping costs and return test results in 7 business days
"Exagen is excited to offer a breakthrough diagnostic that uses CB-CAPs technology to help accurately determine if a patient has lupus," said Ron Rocca, President and CEO. "Because diagnosing lupus is so difficult and early diagnosis is critical in avoiding major organ damage, developing an accurate diagnostic to fill the unmet need for rheumatologists was a top priority. We have been able to do that with Avise SLE and are pleased to take part in helping physicians gain control over this serious disease."